Sirpiglenastat

• CAT Number: I036307
• CAS Number: 2079939-05-0
• Molecular Formula: C22H27N5O5
• Molecular Weight: 441.48
• Purity: ≥95%
• Synonyms: propan-2-yl (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate
• InChI: InChI=1S/C22H27N5O5/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18/h4-7,11-13,19-20,24H,8-10H2,1-3H3,(H,26,28)(H,27,30)/t19-,20-/m0/s1
• InChIKey: LQNMCWOJACNQQM-PMACEKPBSA-N
• SMILES: CC(C)OC(=O)C(CCC(=O)C=[N+]=[N-])NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C

Sirpiglenastat (Cat No.: I036307 ) is a prodrug of a broad-spectrum glutamine antagonist designed to selectively target glutamine metabolism in tumor cells. By inhibiting key glutamine-dependent enzymes, sirpiglenastat disrupts cancer cell energy production, biosynthesis, and redox balance, leading to impaired tumor growth and enhanced immune response. Its tumor-selective activation minimizes systemic toxicity, making it a promising candidate for combination therapies with immuno-oncology agents. Sirpiglenastat is under clinical investigation for treating various solid tumors with glutamine addiction and metabolic vulnerabilities.

Reference

[1]. Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282.
[Content Brief]

[2]. Yumi Yokoyama, et al. DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo. Cancer Res 2021;81(13_Suppl):Abstract nr 1563.